Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8056592 | 0.89 | MMP13 (0.59) | MMP13EPHX2NR1H4 | |
| SCHEMBL8070170 | 0.87 | MMP13 (0.61) | MMP13EPHX2NR1H4 | |
| SCHEMBL3694242 | 0.85 | MMP13 (0.62) | MMP13 | |
| SCHEMBL3688685 | 0.81 | MMP13 (0.63) | MMP13 | |
| SCHEMBL8066880 | 0.79 | XDH (0.56) | MMP13XDH | |
| SCHEMBL4173194 | 0.79 | MMP13 (0.78) | MMP13SLC22A8 | |
| SCHEMBL8072658 | 0.77 | MMP13 (0.53) | MMP13XDH | |
| SCHEMBL6258908 | 0.77 | MMP13 (0.53) | MMP13SLC22A8THRBPOLBSMN1; SMN2 | |
| SCHEMBL4258003 | 0.76 | MMP13 (1.00) | MMP13SLC22A8 | |
| SCHEMBL14448624 | 0.75 | XDH (0.49) | MMP13EPHX2NR1H4XDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101815710-A | Pyrimidine and pyridine derivatives, their pharmaceutical use and compositions | PFIZER | 2010-08-25 | — | — | CN | disclosed |
| US-20090137637-A1 | Tetrazolyl-Methylene Amino Acid Derivatives | PFIZER INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1828162-A1 | TETRAZOLYL-METHYLENE AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006061706-A1 | TETRAZOLYL-METHYLENE AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137637-A1 | Tetrazolyl-Methylene Amino Acid Derivatives | MMP13, MMP11, MMP3 | MMP13 1/4885SLC22A8 1038/4885EPHX2 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.